Adjunctive Perampanel Oral Suspension in Pediatric Patients From ≥2 to

Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel

(2015) Alan B. Ettinger et al.   EPILEPSIA

Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy

(2015) Jacqueline A. French et al.   NEUROLOGY

Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307

(2014) Gregory L. Krauss et al.   EPILEPSIA

The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist

(2014) Philip N. Patsalos   EPILEPSIA

Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305

(2012) Jacqueline A. French et al.   EPILEPSIA

Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304

(2012) J. A. French et al.   NEUROLOGY

Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures

(2012) G. L. Krauss et al.   NEUROLOGY

Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults

(2011) Eva Fernandez et al.   Pharmaceutics

What is the right dose for children?

(2009) Massimo Cella et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY